title: Estrogen receptor-β activation in combination with letrozole blocks the growth of breast cancer tumors resistant to letrozole therapy.
abstract: Treatment with anti-estrogens or aromatase inhibitors (AI) is the main therapeutic strategy used against estrogen receptor ERα-positive breast cancer. Resistance to these therapies presents a major challenge in the management of breast cancer. Little is known about ERβ in breast carcinogenesis. Our aim in this study is to examine potential novel strategies utilizing ERβ activity to overcome AI resistance. We provide evidence that ERβ agonist can reduce the growth of AI-resistant breast cancer cells. Our data further confirm that therapeutic activation of ERβ by DPN, an ERβ agonist, blocks letrozole-resistant tumor growth in a xenograft model. Interestingly, DPN exerted tumor growth inhibition only in the presence of the AI letrozole, suggesting that combination therapy including ERβ activators and AI may be used in the clinical setting treating AI resistant breast cancer. An increase in ERβ levels, with diminished ERα/ERβ ratio, was observed in the tumors from mice treated with DPN/letrozole combination compared to single agents and control. Decreased Cyclin D1 and increased CyclinD1/CDK inhibitors p21 and p27 levels in DPN/letrozole treated tumors were observed, suggesting that the combination treatment may inhibit tumor growth by blocking G1/S phase cell cycle progression. Our data show a decrease in MAPK phosphorylation levels without affecting total levels. In addition to providing evidence suggesting the potential use of ERβ agonists in combination with letrozole in treating AI resistant breast cancer and prolonging sensitivity to AI, we also provide mechanistic evidence supporting the role of ERβ in altering the expression profile associated with resistance.
authors.affiliation: Department of Obstetrics and Gynecology, 7703 Floyd Curl Drive, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.
authors.forename: Hareesh B
authors.initials: HB
authors.lastname: Nair
authors.forename: Nameer B
authors.initials: NB
authors.lastname: Kirma
authors.forename: Manonmani
authors.initials: M
authors.lastname: Ganapathy
authors.forename: Ratna K
authors.initials: RK
authors.lastname: Vadlamudi
authors.forename: Rajeshwar Rao
authors.initials: RR
authors.lastname: Tekmal
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols; D047072:Aromatase Inhibitors / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D018797:Cell Cycle Proteins / Q000032:analysis / Q000378:metabolism; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D047629:Estrogen Receptor beta / Q000819:agonists*; D005260:Female; D006801:Humans; D000077289:Letrozole; D051379:Mice; D008819:Mice, Nude; D009570:Nitriles / Q000627:therapeutic use*; D014230:Triazoles / Q000627:therapeutic use*; D023041:Xenograft Model Antitumor Assays; D011422:Propionates
chemical_list: D047072:Aromatase Inhibitors; D018797:Cell Cycle Proteins; D047629:Estrogen Receptor beta; D000077289:Letrozole; D009570:Nitriles; D014230:Triazoles; C486182:2,3-bis(4-hydroxyphenyl)-propionitrile; D011422:Propionates